INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10590896	
	Filing Date		2006-08-28	
	First Named Inventor	Toshi	hiro USHIJIMA	
	Art Unit		1645	
	Examiner Name	Not Y	Not Yet Assigned	
	Attorney Docket Numb	er	USHIJIMA3	
		-		

U.S.PATENTS										
					U.S.I	AIENIS		r		
Examiner Initial*	Cite N o	Patent Number	Kind Code ¹	Issue D	ate	Name of Patentee or Applicant of cited Document		Relev	es,Columns,Lines where vant Passages or Relev es Appear	
	1								,	
If you wisl	h to ac	dd additional U.S. Pater	nt citatio	n informa	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Appl of cited Document		Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear		
	1		-							
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d butto	on.	
				FOREIG	N PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² j Code ⁴		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T 5	
	1									
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	butto	n ,	·
			NON	N-PATEN	IT LITE	RATURE DO	CUMENTS			
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T 5			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10590896			
Filing Date		2006-08-28			
First Named Inventor	Toshi	Toshihiro USHIJIMA			
Art Unit		1645			
Examiner Name	Not Yet Assigned				
Attorney Docket Number		USHIJIMA3			

/00/	1	Y. IMADA et al., "Enzyme-Linked Immunosorbent Assay Employing a Recombinant Antigen for Detection of Protective Antibody against Swine Erysipelas", Journal of Clinical Microbiology, Vol. 41, No. 11, pp. 5015-5021, November 2003					
/00/	2	M. KESIK et al., "Inclusion bodies from recombinant bacterial as a novel system for delivery of vaccine antigen by the oral route", Immunology Letters, Vol. 91, pp. 197-204, 2004.					
/00/	3	R. KLEEMANN et al., "Characterization of catalytic centre mutants of macrophage migration inhibitory factor (MIF) and comparison to Cys81Ser MIF", Eur. J. Biochem. Vol. 261, pp. 753-766, 1999.					
/00/	4	S. A. KRUPENKO et al., "On the Role of Conserved Histidine 106 in 10-Formyltetrahydrofolate Dehydrogenase Catalysis", Journal of Biological Chemistry, Vol. 276, No. 26, pp. 24030-24037, June 29, 2001.					
/00/	5	J. D. PHILLIPS et al., "Functional consequences of naturally occurring mutations in human uroporphyrinogen decarboxylase", Blood, Vol. 98, No. 12, pp. 3179-3185, December 1, 2001.					
/00/	6	U. RINAS et al., "Cysteine to serine substitutions in basic fibroblast growth factor: effect on inclusion body formation and proteolytic susceptibility during in vitro refolding", BIO/TECHNOLOGY, Vol. 10, No. 4, pp. 435-440, 1992.					
/00/	7	Supplementary European Search Report mailed July 11, 2008. for EP 5709866.7/PCT/JP200500184					
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button					
		EXAMINER SIGNATURE					
Examiner Signature /Oluwatosin Ogunbiyi/ 06/22/2009 Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.							